Treatment of malignant scala posterior brain tumors in children: the chemotherapy of relapsed medulloblastoma with a dibromdulcitol containing drug regime and pharmacokinetic studies of dibromdulcitol in children.
Dibromdulcitol (Elobromol) has favorable pharmacokinetic parameters for the treatment of brain tumors: high spinal fluid/plasma ratio and long half-life in spinal fluid. Oral application makes its administration easy. The drug combination vincristine, procarbazine, and dibromdulcitol proved to be effective in a pilot trial on relapsed medulloblastomas: 8 complete and 4 partial remissions were achieved from 16 cases. The main side effect was granulocytopenia, which was in some cases severe. However, in the dose-schedule we used it did not delay the treatment longer than 1 week.
Schuler
D
D
Department of Paediatrics No. II, Semmelweis University Medical School, Budapest, Hungary.
Somló
P
P
Koóos
R
R
Kálmánchey
R
R
Paraicz
E
E
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002528:Cerebellar Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D008527:Medulloblastoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D008936:Mitolactol / Q000008:administration & dosage / Q000493:pharmacokinetics; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011344:Procarbazine / Q000008:administration & dosage; D012074:Remission Induction; D014057:Tomography, X-Ray Computed; D014750:Vincristine / Q000008:administration & dosage
D011344:Procarbazine; D014750:Vincristine; D008936:Mitolactol